Breaking News Instant updates and real-time market news.

AOBC

American Outdoor Brands

$7.87

-0.29 (-3.55%)

, VSTO

Vista Outdoor

$9.80

-0.1 (-1.01%)

11:17
11/12/19
11/12
11:17
11/12/19
11:17

Gunmakers slide as Supreme Court lets Sandy Hook families sue

The U.S. Supreme Court has refused to block a lawsuit against Remington Arms Co. by family members of those killed in the 2012 Sandy Hook Elementary School massacre, according to multiple media reports. The top court rejected Remington's appeal Tuesday without comment or published dissent, leaving intact a Connecticut Supreme Court ruling that provided the families a path to circumvent a 2005 federal law enacted to shield the gun industry from lawsuits. Publicly traded gunmaker stocks are moving lower following the ruling against privately-held Remington. Public gunmakers and retailers include American Outdoor Brands (AOBC), Vista Outdoor (VSTO) and Sturm, Ruger (RGR).

AOBC

American Outdoor Brands

$7.87

-0.29 (-3.55%)

VSTO

Vista Outdoor

$9.80

-0.1 (-1.01%)

RGR

Sturm, Ruger

$44.50

-0.64 (-1.42%)

AOBC American Outdoor Brands
$7.87

-0.29 (-3.55%)

09/06/19
KEYB
09/06/19
NO CHANGE
KEYB
Retail firearm background checks rose more than expected in August, says Keybanc
NICS background checks conducted by the FBI, which is a proxy for retail firearm demand, rose an adjusted 15.2% in August, according to Keybanc analyst Brett Andress. This was above his expectation for mid-single digit growth. State-level data also supports broad-based strength, with all but two states tracking positively, said the analyst, who added that comparisons ease further into September and October. Publicly traded companies in the gun space include American Outdoor Brands (AOBC), Sturm, Ruger (RGR), and Vista Outdoor (VSTO).
10/09/19
CHLM
10/09/19
UPGRADE
Target $10
CHLM
Buy
American Outdoor Brands upgraded to Buy from Hold at Craig-Hallum
Craig-Hallum analyst Steven Dyer upgraded American Outdoor Brands to Buy from Hold with an unchanged price target of $10.
10/09/19
10/09/19
UPGRADE
Target $10

Buy
American Outdoor Brands upgraded to Buy on valuation, catalysts at Craig-Hallum
As previously reported, Craig-Hallum analyst Steven Dyer upgraded American Outdoor Brands to Buy from Hold, with an unchanged price target of $10. The analyst believes valuation is "extremely attractive" and thinks there is a compelling near-term opportunity with potential catalysts upcoming even though he continues to have concerns about a potential longer-term secular decline in firearms.
10/09/19
10/09/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Roku (ROKU) upgraded to Outperform from Neutral at Macquarie with analyst Tim Nollen saying the shift to connected television viewing that has been underway in the U.S. for the past few years will follow internationally in the coming years. 2. Chipotle (CMG) upgraded to Hold from Underperform at Gordon Haskett with analyst Jeff Farmer saying the company's sales momentum makes the bear thesis on shares "increasingly untenable." 3. Sleep Number (SNBR) upgraded to Outperform from Market Perform at Raymond James with analyst Bobby Griffin saying Sleep Number's pullback over the last few months creates a more favorable risk/reward setup heading into Q3 earnings and adds that he continues to have a favorable view of the company's business model and product offering, particularly as consumers focus on health and wellness. 4. American Outdoor Brands (AOBC) upgraded to Buy from Hold at Craig-Hallum with analyst Steven Dyer saying he believes valuation is "extremely attractive" and thinks there is a compelling near-term opportunity with potential catalysts upcoming even though he continues to have concerns about a potential longer-term secular decline in firearms. 5. Fannie Mae (FNMA) and Freddie Mac (FMCC) upgraded to Market Perform from Underperform at Keefe Bruyette. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
VSTO Vista Outdoor
$9.80

-0.1 (-1.01%)

07/09/19
07/09/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Chewy (CHWY) was initiated with an Outperform at William Blair and Wells Fargo, an Overweight at JPMorgan, a Buy at BofA/Merrill and UBS, an Equal Weight at Morgan Stanley and Barclays, a Market Perform at Raymond James, a Sector Perform at RBC Capital, a Hold at Jefferies, and a Neutral at Nomura Instinet. 2. Intellia Therapeutics (NTLA) initiated with an Outperform at Baird. 3. Slack Technologies (WORK) initiated with a Perform at Oppenheimer. 4. AAR Corp. (AIR) initiated with a Buy at Stifel. 5. Vista Outdoor (VSTO) initiated with a Buy at Lake Street. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/21/19
LSCM
08/21/19
NO CHANGE
Target $9
LSCM
Buy
Vista Outdoor would be attractive candidate for takeover, says Lake Street
Lake Street analyst Mark Smith said the selloff in Vista Outdoor shares since the announcement of the sale of the Savage firearms business in early July has been overdone. He said a large part of the Q1 earnings miss and lower guidance was due to the divested firearms business, but this should not have come as a surprise since management had previously given a warning regarding the divestiture and its impact. His analysis of 33 M&A transactions over the last eight years for businesses similar to Vista leads him to conclude that the company would be an attractive takeover candidate, noted Smith, who keeps a Buy rating and $9 price target on the stock.
10/11/19
DADA
10/11/19
INITIATION
Target $6.5
DADA
Neutral
Vista Outdoor initiated with a Neutral rating at DA Davidson
DA Davidson analyst Michael Kawamoto initiated coverage of Vista Outdoor with a Neutral rating and $6.50 price target. The analyst believes an inflection point is near, on both revenue growth and margins, but prefers to wait for better visibility to the size and timing of this acceleration before getting more constructive on the shares.
RGR Sturm, Ruger
$44.50

-0.64 (-1.42%)

TODAY'S FREE FLY STORIES

STOK

Stoke Therapeutics

$28.91

3.99 (16.01%)

10:04
12/08/19
12/08
10:04
12/08/19
10:04
Hot Stocks
Stoke Therapeutics presents STK-001 preclinical data in Dravet syndrome »

Stoke Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AUTL

Autolus Therapeutics

$14.60

-0.18 (-1.22%)

09:25
12/08/19
12/08
09:25
12/08/19
09:25
Hot Stocks
Autolus announces new data highlighting progress on AUTO3 »

Autolus Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

AGIO

Agios Pharmaceuticals

$40.93

0.81 (2.02%)

09:22
12/08/19
12/08
09:22
12/08/19
09:22
Hot Stocks
Agios says proof-of-concept has been established for mitapivat »

Agios Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 13

    Dec

ZIOP

Ziopharm

$5.16

0.06 (1.18%)

09:20
12/08/19
12/08
09:20
12/08/19
09:20
Hot Stocks
Ziopharm reports pre-clinical data of Rapid Personalized Manufacture »

Ziopharm Oncology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

TGTX

TG Therapeutics

$7.11

-0.57 (-7.42%)

09:18
12/08/19
12/08
09:18
12/08/19
09:18
Hot Stocks
TG Therapeutics reports triple therapy data from Phase I/II study of ublitux »

TG Therapeutics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

KPTI

Karyopharm

$16.30

-1.15 (-6.59%)

09:16
12/08/19
12/08
09:16
12/08/19
09:16
Hot Stocks
Karyopharm says four posters will be presented at ASH »

Karyopharm Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPHA

Innate Pharma

$6.30

(0.00%)

09:13
12/08/19
12/08
09:13
12/08/19
09:13
Hot Stocks
Innate Pharma reports long-term data from Phase III trial of Lumoxiti »

Innate Pharma shared new,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REGN

Regeneron

$372.26

4.02 (1.09%)

09:11
12/08/19
12/08
09:11
12/08/19
09:11
Hot Stocks
Regeneron reports initial data for REGN5458 in myeloma patients »

Regeneron Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

BPMC

Blueprint Medicines

$78.50

3.92 (5.26%)

09:09
12/08/19
12/08
09:09
12/08/19
09:09
Hot Stocks
Blueprint reports 77% overall response rate in 48 patients from Explorer trial »

Blueprint Medicines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

BPMC

Blueprint Medicines

$78.50

3.92 (5.26%)

09:06
12/08/19
12/08
09:06
12/08/19
09:06
Hot Stocks
Blueprint announces initial data from Phase 2 Pioneer trial in mastocytosis »

Blueprint Medicines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

PCG

PG&E

$9.65

-0.13 (-1.33%)

08:12
12/08/19
12/08
08:12
12/08/19
08:12
Periodicals
PG&E settlement threatens bondholders plan, WSJ reports »

PG&E's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

SYRS

Syros Pharmaceuticals

$4.60

-0.02 (-0.43%)

08:08
12/08/19
12/08
08:08
12/08/19
08:08
Hot Stocks
Syros announces fetal hemoglobin repressor using gene control platform »

Syros Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

ABBV

AbbVie

$86.97

0.3 (0.35%)

08:06
12/08/19
12/08
08:06
12/08/19
08:06
Hot Stocks
AbbVie says post-hoc analysis supports benefit of venetoclax in combination »

AbbVie presented…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHHBY

Roche

$0.00

(0.00%)

08:03
12/08/19
12/08
08:03
12/08/19
08:03
Hot Stocks
Genentech reports data from two Phase III Venclexta studies in leukemia »

Genentech, a member of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

  • 10

    Dec

  • 16

    Dec

ORTX

Orchard Therapeutics

$11.85

0.37 (3.22%)

07:59
12/08/19
12/08
07:59
12/08/19
07:59
Hot Stocks
Orchard to present data from multiple programs at ASH meeting »

Orchard Therapeutics said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRRA

Sierra Oncology

$0.49

0.1035 (27.13%)

06:55
12/08/19
12/08
06:55
12/08/19
06:55
Conference/Events
Sierra Oncology to hold an analyst and investor event »

Analyst and Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

RUHN

Ruhnn

$6.19

-0.2 (-3.13%)

04:55
12/08/19
12/08
04:55
12/08/19
04:55
Conference/Events
Ruhnn management to meet with Mizuho »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Dec

SRRA

Sierra Oncology

$0.49

0.1035 (27.13%)

04:55
12/08/19
12/08
04:55
12/08/19
04:55
Conference/Events
Sierra Oncology to hold an analyst and investor event »

Analyst and Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

04:55
12/08/19
12/08
04:55
12/08/19
04:55
Conference/Events
Piper Jaffray biotech analysts to hold a KOL luncheon »

Biotech Analysts hold a…

MGTA

Magenta Therapeutics

$13.29

0.3 (2.31%)

19:31
12/07/19
12/07
19:31
12/07/19
19:31
Hot Stocks
Magenta reports results from MGTA-145 stem cell mobilization program »

Magenta Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

PFE

Pfizer

$38.29

0.26 (0.68%)

, BMY

Bristol-Myers

$59.94

0.435 (0.73%)

19:29
12/07/19
12/07
19:29
12/07/19
19:29
Hot Stocks
Bristol-Myers Squibb-Pfizer Alliance reports analysis of Eliquis »

The Bristol-Myers…

PFE

Pfizer

$38.29

0.26 (0.68%)

BMY

Bristol-Myers

$59.94

0.435 (0.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 08

    Dec

  • 09

    Dec

  • 11

    Dec

UMRX

Unum Therapeutics

$0.70

0.0177 (2.61%)

19:25
12/07/19
12/07
19:25
12/07/19
19:25
Hot Stocks
Unum Therapeutics announces Phase 1 clinical updates for T-cell therapies »

Unum Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

MGTA

Magenta Therapeutics

$13.29

0.3 (2.31%)

19:25
12/07/19
12/07
19:25
12/07/19
19:25
Conference/Events
Magenta Therapeutics to hold an investor and analyst event »

Investor and Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

AUTL

Autolus Therapeutics

$14.60

-0.18 (-1.22%)

19:23
12/07/19
12/07
19:23
12/07/19
19:23
Hot Stocks
Autolus presents new data on T cell therapies in leukemia, lymphoma »

Autolus Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

  • 09

    Dec

BMY

Bristol-Myers

$59.94

0.435 (0.73%)

19:19
12/07/19
12/07
19:19
12/07/19
19:19
Hot Stocks
Bristol-Myers says lisocabtagene maraleucel study met both endpoints »

Bristol-Myers Squibb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 08

    Dec

  • 09

    Dec

  • 11

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.